Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the efficacy and tolerability of fMRI-targeted repetitive transcranial magnetic stimulation (rTMS) in the treatment of depressive symptoms in service members with a history of concussive traumatic brain injury (TBI).

Up to ninety participants will be randomized to active or sham treatment. Participants randomized into the active group will receive 20 sessions of left-sided dorsolateral prefrontal cortex (DLFPC) high-frequency rTMS, followed by right-sided DLFPC low-frequency rTMS. The DLPFC treatment area will be identified by using individual subject-level resting state network estimation (Hacker et al., 2013). Participants randomized into the sham treatment group will receive 20 sham treatments designed to have similar sound and tactile sensation, without producing active treatment. Participants will also be asked to complete regular follow-up evaluations for up to a total of six follow-up sessions. Those who do not respond to the treatment will have the option to receive active treatment through this study regardless of group assignment to active or sham.


Clinical Trial Description

This study aims to investigate the efficacy and tolerability of individual connectome-targeted repetitive transcranial magnetic stimulation (ICT-rTMS) treatment to enhance the rehabilitation of service members with symptoms of depression and history of concussive traumatic brain injury (TBI).

This will be a multi-site, double-blinded, sham-controlled, prospective, randomized interventional trial. Up to ninety participants will be block randomized to active (ICT-rTMS) or sham treatment. Participants will receive 20 sessions of ICT-rTMS over approximately 5 weeks.

Resting-state functional magnetic resonance imaging (rsfMRI) and structural MRI will be obtained at baseline to allow for the calculation of connectome-targeted treatment coordinates and ensure the absence of structural abnormalities. The rsfMRI scan at baseline will also be used to establish the baseline for the secondary imaging outcome measures.

Treatment sessions will consist of high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation for 4,000 pulses followed by low-frequency right DLPFC stimulation for 1,000 pulses for a total stimulation time of approximately one hour per session. This protocol was chosen based on a recent meta-analysis (Brunoni et al., 2017) indicating that amongst the various treatment protocols, priming the low frequency right hemisphere stimulation with a high frequency left hemisphere stimulation led to the greatest efficacy for treatment of Major Depressive Episodes. Additionally, the overwhelming majority of the literature in TMS for depression targets the stimulation to DLPFC and the FDA has approved repetitive transcranial magnetic stimulation (rTMS) to DLPFC for the treatment of medication-resistant major depressive disorder (MDD).

The primary outcome will be change in depression severity from baseline to post-treatment. The primary analysis will be a comparison between the ICT-rTMS and sham groups. Secondary outcome measures utilized will include cognitive, quality of life, and emotional regulation measures, as well as imaging changes. Additional analyses will include durability of effects during the 6 months following treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03523507
Study type Interventional
Source Uniformed Services University of the Health Sciences
Contact Charline E Simon, MA
Phone (301) 295-6439
Email charline.simon.ctr@usuhs.edu
Status Not yet recruiting
Phase N/A
Start date August 1, 2018
Completion date May 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Not yet recruiting NCT03035838 - Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury Early Phase 1
Not yet recruiting NCT03227354 - Validation of Non-invasive Absolute Intracranial Pressure Monitoring N/A
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Active, not recruiting NCT02339220 - The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment N/A
Not yet recruiting NCT02698449 - Neurorehabilitation After Traumatic Brain Injury: Functional Magnetic Resonance Imaging Study N/A
Completed NCT02836951 - Rapid Diagnostics for Traumatic Brain Injury (TBI) N/A
Recruiting NCT03373331 - Treating Emotional Processing Impairments in Individuals With TBI N/A
Recruiting NCT02613936 - Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury N/A
Recruiting NCT02465242 - Pupillometry for the Prediction of Neurologic Outcomes in Severe Traumatic Brain Injury N/A
Recruiting NCT02424656 - Alterations in the Brain's Connectome After Severe Traumatic Brain Injury N/A
Recruiting NCT02255799 - Multicenter Evaluation of Memory Remediation After TBI With Donepezil Phase 3
Not yet recruiting NCT02148783 - Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI Phase 2
Withdrawn NCT02148367 - Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI Phase 2
Terminated NCT02218216 - TBI MR Study 3 Houston Methodist N/A
Active, not recruiting NCT01606111 - The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Phase 4
Active, not recruiting NCT01874847 - PLAY GAME: Post-concussion Syndrome in Youth - Assessing the GABAergic Effects of Melatonin Phase 2/Phase 3
Active, not recruiting NCT01618786 - Flooring for Injury Prevention Trial N/A
Completed NCT02262507 - Concussion Device Audiological Measures N/A